Investigation into the dissolution rate increase on storage of Wellbutrin SR 100 mg tablets.
The Food and Drug Administration (FDA) approved the New Drug Application for Wellbutrin sustained release (SR) 100 mg tablets on October 4, 1996. However, by 1998, the FDA expressed concern about the stability of this drug product based on an increase in the dissolution profile on storage. Data submitted in the annual report showed that this drug product could not meet the expiry of 18 months at the International Committee on Harmonization storage condition of 25 degrees C/60% relative humidity. The FDA mandated a 12-month expiry and GlaxoWellcome tightened this further by instituting an expiry of 9 months. The FDA also requested a long-term solution to the stability of Wellbutrin SR 100 mg tablets. Investigations via colloidal solutions revealed that the dissolution rate increase on storage occurred due to acid hydrolysis of the release controlling polymer. This drug product was successfully reformulated by slowing the initial dissolution rate and having an increased ratio of release controlling polymer to acid stabilizer. The reformulation used the same ingredients and manufacturing unit processes as the original formulation. The reformulated drug product was approved by the FDA on October 11, 2000 with an 18-month shelf-life. The shelf-life was extended to 36 months in an annual update to the FDA on December 1, 2005.
Wells
Mickey L
ML
Pharmaceutical Development, GlaxoSmithKline, Inc., Research Triangle Park, North Carolina, USA. mickey-wells@uiowa.edu
Williams
Sandra O
SO
Sanftleben
Ronald A
RA
Balik
Samuel B
SB
Evans
Barry A
BA
D016642:Bupropion; D002626:Chemistry, Pharmaceutical; D015987:Effect Modifier, Epidemiologic; D004364:Pharmaceutical Preparations / Q000592:standards*; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
D004364:Pharmaceutical Preparations; D013607:Tablets; D016642:Bupropion